C. Ronald Kahn is a world-recognized expert in diabetes/obesity research and a preeminent investigator of insulin signal transduction and mechanisms of altered signaling in metabolic disease. Kahn is currently the Chief Academic Officer, Head of the Section on Integrative Physiology and Metabolism at Joslin Diabetes Center and the Mary K. Iacocca Professor of Medicine at Harvard Medical School.
Kahn served as Research Director of the Joslin Diabetes Center from 1981 to 2000, and President of Joslin from 2001 to 2007. He has received more than 70 awards and honors, including election to the National Academy of Science and Institute of Medicine, Wolf Prize in Medicine, Rolf Luft Award, Allyn Taylor International Prize in Medicine, Manpei Suzuki and Hamm International Awards, and the highest honors of the American Diabetes Association, EASD, Endocrine Society and the American Association of Clinical Endocrinologists. He has authored more than 600 original articles and 200 reviews and chapters. Dr. Kahn also served as chair of the Congressionally-established Diabetes Research Working Group, which developed the strategic plan for all federally-funded diabetes research, as well as President of the American Society of Clinical Investigation.
Dr. Kahn holds undergraduate and medical degrees from the University of Louisville and did his training at Barnes Hospital/Washington University and the NIH. He has honorary Doctorates from the University of Paris, University of Louisville, University of Geneva, University of Copenhagen, Louisiana State University, and Washington University in St. Louis, and is an honorary Professor and Director of the Diabetes Center at Peking University School of Medicine.
The Business of The FASEB Journal
BenchSci Helps Increase Discoverability of Content
BenchSci, an AI discoverability platform that helps scientists design better experiments by decoding scientific papers and extracting usage data for biological compounds and related figures, has partnered with The FASEB Journal. This partnership aims to increase discoverability of relevant scientific compounds discussed within The FASEB Journal-published articles.
“’Publish or perish’ is a driving force for scientists, but funding resources are limited. Scientists need to find the right products for their research, and fast. BenchSci prevents wasted time and resources by bringing scientists to the relevant information they need in a fraction of the time,” said Liran Belenzon, CEO of BenchSci. “The partnership between BenchSci and The FASEB Journal is a great first step to generating a more comprehensive database and allowing scientist to harness the power of the BenchSci platform to accelerate the pace of their research.” Learn more about BenchSci.